Dr. Reddy’s Q4FY23 results: Consolidated PAT at ₹959 cr, rises by 10-folds YoY; 800% dividend for shareholders

Pharma giant, Dr Reddy’s Lab posted a consolidated net profit of ₹960.1 crore for the fourth quarter of FY23, rising by multi-fold on a year-on-year basis. Revenue also picked up traction YoY. However, the Q4FY23 performance was feeble on a quarter-on-quarter basis.

The company’s Q4 PAT jumped by 9.9 times or 889.79% from a profit of ₹97 crore in Q4FY23. However, sequentially, the PAT witnessed a decline as against ₹1,243.9 crore in Q3FY23.

The revenue from operations rose by 16 per cent to ₹6,296.8 crore in the quarter under review, as compared to ₹5,436.8 crore in the corresponding period of last fiscal.

Meanwhile, total expenses were down by 13 per cent at ₹2,362 crore as compared to ₹2,722 crore from the year-ago period.

The Operating margin, calculated as Ebitda (Earnings Before Interest, Taxes, Depreciation, and Amortization) was up 1 percent at ₹1,631 crore, while margin was at 25.9 per cent as against 23.9 percent a year ago.

The company has recommended a final dividend of ₹40 (800 per cent) per equity share of ₹5 each for the financial year 2022-23. The dividend will be paid on or after five days from the date of declaration of the final dividend by the shareholders at the annual general meeting (AGM).

The company’s scrip ended 1.33 per cent down at ₹4,865 on BSE.

Leave a Reply

Your email address will not be published. Required fields are marked *